Rhythm Pharmaceuticals Announces MHLW Approval of IMCIVREE® (setmelanotide) for Patients with Acquired Hypothalamic Obesity (HO) in Japan
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/23/2026
- Dow, S&P 500 fall, tech steadies to end rocky week
- Meta's capital-raising plans expose a major weakness in the AI boom
- Brent crude jumps to highest since April on Houthi attacks, UAE oil spill
- BofA flags further downside risk for stocks, yields and dollar
- SpaceX cell-site ambitions lift tower stocks and weigh on carriers
| (NASDAQ: RYTM) | Delayed: 88.98 -1.92 (2.11%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $90.90 | 52 Week High | $ | |||
| Open | $89.88 | 52 Week Low | $ | |||
| Day High | $90.21 | P/E | N/A | |||
| Day Low | $88.56 | EPS | $ | |||
| Volume | 236,241 | |||||
